Fig. 6

GKN2 represses the tumorigenicity of GC cells under stress condition. a Forced expression of GKN2 suppresses the tumorigenicity of MGC in nude mice with PL treatment (n = 5). b-c Tumor volume and weights of xenografts tumors of MGC-con and MGC-GKN2 are significantly different. d Representative images of staining of HE, GKN2 and Ki67 in xenograft tumors of MGC-con and MGC-GKN2. Scale bar: 200 μm. e Silencing of GKN2 enhances the tumorigenicity of SGC in nude mice (n = 5). Mice were intraperitoneal injected with acetylcysteine (AC, 300 mg/kg) 2 h before administration of PL. (f-g) Tumor volume and weight of xenografts tumors of SGC-con and SGC-cas9-GKN2 were significantly different. Complementation of AC enhanced effect of the tumorigenicity in vivo. (h) Representative images of staining of HE, GKN2 and Ki67 in xenograft tumors. Scale bar: 200 μm. (i) IHC staining of human GC tissues using GKN2-specific antibody; classification of samples according to the intensity of staining of GKN2 expression. Scale bar: 200 μm. j Kaplan-Meier curves for GC patients’ overall survival in the patients with high GKN2 expression and low GKN2 expression (n = 121, p = 0.006). The endpoint event was defined as mortality **p < 0.01, ***p < 0.001